• Obama vs. GOP...or GDP?     Friday, 22 Jun 2012 | 7:15 PM ET

    CNBC's Eamon Javers reports on the Washington Post's story analyzing Bain Capital's role in outsourcing jobs; and as President Obama lays out his battle plan against Romney, is the GDP getting enough attention? Jared Bernstein, former Biden chief economist; Steve Malanga, Manhattan Institute senior fellow; and Jim Garland, Sharp Details CEO, share their opinions.

  • Gigantic movie house, The Weinstein Company, has just secured $225 million in financing from UBS and Union Bank. CEO Harvey Weinstein discusses how his company will use the money to grow their business, the company's overseas success, the "Intouchables," and politics.

  • What's the Market's Mood?     Friday, 22 Jun 2012 | 3:44 PM ET

    Insight on the market's next direction, with Christian Thwaites, Sentinel Investments, and Hank Smith, Haverford Investments.

  • Facebook's Big Bounce     Friday, 22 Jun 2012 | 2:45 PM ET

    If you'd made a bold call and bought then, you'd actually be making money from Facebook, with Howard Lindzon, CEO of Stocktwits.

  • Darden CEO: Growth Not as Robust as Wanted     Friday, 22 Jun 2012 | 7:10 AM ET

    "What we see is a cautious consumer," says Clarence Otis, Darden Restaurants CEO, discussing the slowdown in restaurant sales; the impact of rising commodities prices; and his company's "mixed" fourth quarter earnings results.

  • The Border Battle     Thursday, 21 Jun 2012 | 7:38 PM ET

    CNBC's John Harwood reports on the details of Romney's immigration plan; and Henry Cisneros, CityView chairman & CEO; and T.J. Rodgers, Cypress Semiconductor CEO, weigh in on the presidential election and border militarization reforms.

  • "I think the pipeline master limited partnerships could be a terrific place to wait out the rocky markets," says Mad Money host Jim Cramer. Kelcy Warren, Energy Transfer Partners CEO, discusses MLPs and the state of natural gas.

  • Red Hat Earnings Beat the Street     Thursday, 21 Jun 2012 | 5:30 PM ET

    Red Hat CEO James Whitehurst discusses his company's latest earnings beat and strong position in Europe.

  • Volatility to Continue Amid Euro Crisis?     Thursday, 21 Jun 2012 | 3:15 PM ET

    George Gatch, JPMorgan Asset Mgmt. Global Funds CEO, discusses what investors should be focused on at this stage of the euro zone crisis.

  • Red Robin CEO: Consumers 'Skittish'     Thursday, 21 Jun 2012 | 2:45 PM ET

    Stephen Carley, Red Robin CEO, says the U.S. consumer is a bit "skittish and volatile."

  • Deal With European Debt ‘En Masse’: Citi's Pandit Thursday, 21 Jun 2012 | 1:43 PM ET

    Citigroup CEO Vikram Pandit told CNBC that the solution to the grinding European debt crisis requires dealing with the region’s sovereign debt ‘en masse.’

  • Under Armour CEO on New Sneaker     Wednesday, 20 Jun 2012 | 3:40 PM ET

    Kevin Plank, Under Armour founder & CEO, discusses the new UA Spine RPM footwear collection, with CNBC's Darren Rovell.

  • Caterpillar CEO on Fed, Russia & Dividends     Wednesday, 20 Jun 2012 | 1:22 PM ET

    Doug Oberhelman, Caterpillar chairman & CEO, offers insight on everything from the Fed, economy and dividends.

  • Welch: 'Housing is Going to Pick Up'     Wednesday, 20 Jun 2012 | 7:51 AM ET

    Jack Welch, former GE chairman & CEO, shares his thoughts on the continued financial crisis in Europe; and the outlook on the U.S. economic recovery.

  • Teekay CEO on Navigating Growth in LNG     Wednesday, 20 Jun 2012 | 6:40 AM ET

    "We are investing a lot of money," says Peter Evensen, Teekay Corporation CEO, discussing how his company is profiting in the shipping space, despite facing strong economic headwinds, and benefiting from the increase in liquid natural gas production.

  • Acorda CEO Projects $255 Million From AMPYRA     Tuesday, 19 Jun 2012 | 6:45 PM ET

    Ron Cohen, Acorda Therapeutics president & CEO, offers insight on just how much potential his company's multiple sclerosis drug "AMPYRA" has in the pharmaceutical market.

  • Cramer Examines BioMarin Pharmaceuticals     Tuesday, 19 Jun 2012 | 6:15 PM ET

    Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses his company's efforts to develop treatment products for Lysosomal Storage Disorders. "We are the opposite of big pharma, we look at a significant improvement in a small patient population," says Bienaime.

  • Sanofi CEO's M&A Outlook     Tuesday, 19 Jun 2012 | 4:15 PM ET

    Christopher Viehbacher, Sanofi CEO, discusses his company's acquisition of Genzyme and where he sees further deals in the pharmaceutical industry.

  • Fed to the Rescue?     Tuesday, 19 Jun 2012 | 3:05 PM ET

    Insight on the Fed's meeting, with Thomas Belesis, John Thomas Financial CEO, and CNBC's Rick Santelli, Steve Liesman & Brian Shactman.

  • JC Penney Ad Troubles     Tuesday, 19 Jun 2012 | 2:51 PM ET

    The "Street Signs" crew and Jan Kniffen, J. Rogers Kniffen WWE CEO, discuss the recent decline in JC Penney, whether its advertising strategies reach its customers, and the departure of the company's president Michael Francis.

Most Popular Video

Thursday, 24 Apr 2014 | 1:05 AM ET

Jerry Braakman, chief investment officer at First American Trust, says Apple and Facebook reported "great" results and owning technology stocks is still attractive.

Thursday, 24 Apr 2014 | 12:16 AM ET

Manpreet Gill, Senior Investment Strategist at Standard Chartered Bank, attributes the decline of Japanese shares to the lack of a TPP agreement during U.S. President Barack Obama's visit to Tokyo.

Wednesday, 23 Apr 2014 | 3:00 PM ET

CNBC's Becky Quick discusses Warren Buffett's feelings about Coke, IBM and his general sentiment about the market.